<DOC>
	<DOCNO>NCT00556322</DOCNO>
	<brief_summary>This 2 arm study evaluate efficacy , safety , pharmacokinetics Tarceva standard care chemotherapy patient advance , recurrent , metastatic NSCLC experience disease progression failure platinum-based chemotherapy.Eligible patient randomize receive either Tarceva 150mg po daily , comparator ( either Alimta 500mg/m2 every 3 week , Taxotere 75mg/m2 every 3 week ) . The anticipated time study treatment disease progression , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Standard Care Chemotherapy Patients With Advanced , Recurrent , Metastatic Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>adult patient &gt; =18 year age ; histologically document , locally advanced recurrent metastatic NSCLC ; measurable disease ; disease progression 14 cycle platinumbased chemotherapy . malignancy within last 5 year ; unstable systemic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>